Pete O Donald
Foot & Ankle Surgery · Port Neches, TXNPI 1992111538
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 29 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Smith+Nephew at 32.1% of the total. Reporting peaked in 2022 at $238 and has fallen 56.1% since, to $104 in 2025. That places this record below the midpoint for foot & ankle surgery clinicians in TX, where the typical reported total is $3,901.
Across 29 payments — averaging $21.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$199
- Johnson & Johnson$105
- Kowa Pharmaceuticals America, Inc.$89
- Bioventus LLC$56
- Treace Medical Concepts, Inc.$42
- Kerecis Limited$39
- plus $91 from 4 others
What the payments were for
- Food & beverage$620100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 10 | $199 |
| Johnson & Johnson | 4 | $105 |
| Kowa Pharmaceuticals America, Inc. | 4 | $89 |
| Bioventus LLC | 2 | $56 |
| Treace Medical Concepts, Inc. | 2 | $42 |
| Kerecis Limited | 2 | $39 |
| Medinc Of Texas | 2 | $35 |
| Inari Medical, Inc. | 1 | $20 |
| Convatec Inc. | 1 | $18 |
| Nevro Corp. | 1 | $17 |
How this compares
$620 in reported general payments places this provider in the 15th percentile of 684 foot & ankle surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gentamicin Sulfate | 141 | $5,189 |
| Doxycycline Monohydrate | 203 | $2,632 |
| Gabapentin | 242 | $2,219 |
| Ammonium Lactate | 84 | $1,708 |
| Naproxen | 108 | $907 |
| Meloxicam | 253 | $890 |
| Terbinafine Hcl | 33 | $839 |
| Clindamycin Hcl | 57 | $588 |
| Colchicine | 25 | $550 |
| SsdSilver Sulfadiazine | 20 | $493 |
| Nitroglycerin PatchNitroglycerin | 13 | $374 |
| Ciprofloxacin Hcl | 62 | $362 |
| Allopurinol | 35 | $327 |
| Triamcinolone Acetonide | 50 | $302 |
| Mupirocin | 30 | $201 |
Paid to pharmacies, not to this prescriber.
Other foot & ankle surgery in Port Neches
- William McGarveyKaty$3.5M
- Eugene CurryDallas$3.1M
- Graham HamiltonEdinburg$2.1M
- Mark DaltonAustin$1.9M
- Kevin VarnerHouston$1.1M
- Paul KimDallas$928K
- Sherman NaglerHouston$602K
- John EarlyDallas$553K
- Michael DowneySouthlake$475K
- Abdul NurudeenHouston$404K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.